Share Price and Basic Stock Data
Last Updated: January 8, 2026, 7:49 pm
| PEG Ratio | 1.04 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Choksi Laboratories Ltd operates in the Medical Research Services industry, with its share price currently at ₹126 and a market capitalization of ₹87.6 Cr. The company has shown a consistent revenue growth trajectory, recording sales of ₹34.44 Cr for the financial year ending March 2023, which rose to ₹36.70 Cr in March 2024 and is projected to reach ₹41.78 Cr in March 2025. Quarterly sales figures indicate fluctuations, with a notable peak of ₹11.12 Cr in March 2025, showcasing the company’s ability to capitalize on market opportunities. However, the most recent quarterly sales stood at ₹7.95 Cr in September 2023, indicating a decline from the previous quarter. The company has also reported an operating profit margin (OPM) of 26.35%, reflecting a robust operational efficiency compared to typical sector ranges.
Profitability and Efficiency Metrics
Choksi Laboratories Ltd’s profitability metrics reflect a mixed performance. The company reported a net profit of ₹1.66 Cr for the trailing twelve months, with a net profit margin of 3.64% for March 2025. This is a decline from 9.32% in March 2023, indicating a need for enhanced cost management. The return on equity (ROE) stood at 6.63%, while the return on capital employed (ROCE) was reported at 9.20%, both of which are relatively low compared to industry benchmarks, suggesting potential inefficiencies in capital utilization. The interest coverage ratio (ICR) of 4.27x indicates that the company comfortably meets its interest obligations, which is a positive sign for its financial health. However, the cash conversion cycle (CCC) of -474.95 days raises concerns regarding working capital management, suggesting that the company may face liquidity risks.
Balance Sheet Strength and Financial Ratios
Choksi Laboratories Ltd’s balance sheet reflects a total debt of ₹28.87 Cr against reserves of ₹17.53 Cr, indicating a debt-to-equity ratio of 1.19x. This level of leverage is higher than typical sector norms and may pose risks in terms of financial stability. The company reported a book value per share of ₹33.89, which translates to a price-to-book value (P/BV) ratio of 3.55x, suggesting that the stock is trading at a premium compared to its net asset value. Additionally, the current ratio of 0.68 and quick ratio of 0.66 indicate potential liquidity challenges, as these ratios fall below the ideal benchmark of 1. The company has consistently maintained a reasonable interest coverage ratio, further underscoring its ability to service debt, but the increasing borrowings trend could lead to higher financial costs in the future.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Choksi Laboratories Ltd indicates a stable promoter holding of 31.48%, which has remained unchanged over the recent quarters. The foreign institutional investors (FIIs) have gradually increased their stake from 0% in December 2022 to 5.69% by September 2025, which may reflect growing investor confidence in the company’s long-term prospects. Public shareholding stood at 62.83%, with a total of 4,067 shareholders, suggesting a diversified ownership structure. However, the declining public shareholding percentage from 68.51% in December 2022 to 62.83% in September 2025 may raise concerns about investor sentiment. The gradual increase in FII participation could be seen as a positive signal, indicating that institutional investors are recognizing the potential in Choksi Laboratories.
Outlook, Risks, and Final Insight
Choksi Laboratories Ltd faces a mixed outlook characterized by both growth opportunities and significant risks. The company’s revenue growth trajectory suggests potential for continued expansion, especially if operational efficiencies can be improved. However, the declining net profit margin and rising debt levels pose considerable risks to financial stability. The high cash conversion cycle indicates potential liquidity challenges that could impact operations. Furthermore, increasing competition in the medical research services sector could pressure margins further. The company’s strong interest coverage ratio provides some comfort, but sustained performance improvements are essential. A focus on cost management, operational efficiency, and prudent financial practices will be critical for navigating these challenges and enhancing shareholder value in the future.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Choksi Laboratories Ltd | 88.3 Cr. | 127 | 237/97.6 | 53.2 | 35.2 | 0.00 % | 9.20 % | 6.63 % | 10.0 |
| Vimta Labs Ltd | 2,688 Cr. | 602 | 903/372 | 36.0 | 93.5 | 0.17 % | 25.2 % | 19.4 % | 2.00 |
| Industry Average | 2,688.00 Cr | 364.50 | 44.60 | 64.35 | 0.09% | 17.20% | 13.02% | 6.00 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8.68 | 7.84 | 9.78 | 8.88 | 7.95 | 8.79 | 11.12 | 10.74 | 9.26 | 10.38 | 11.40 | 11.24 | 11.12 |
| Expenses | 6.35 | 5.61 | 6.30 | 6.45 | 5.84 | 6.55 | 7.63 | 7.91 | 6.90 | 7.84 | 7.90 | 8.34 | 8.19 |
| Operating Profit | 2.33 | 2.23 | 3.48 | 2.43 | 2.11 | 2.24 | 3.49 | 2.83 | 2.36 | 2.54 | 3.50 | 2.90 | 2.93 |
| OPM % | 26.84% | 28.44% | 35.58% | 27.36% | 26.54% | 25.48% | 31.38% | 26.35% | 25.49% | 24.47% | 30.70% | 25.80% | 26.35% |
| Other Income | 0.02 | 0.10 | 2.26 | 0.00 | 0.05 | 0.00 | 0.06 | 0.01 | 0.01 | 0.01 | 0.04 | 0.00 | 0.01 |
| Interest | 0.87 | 0.93 | 0.94 | 0.82 | 0.74 | 0.67 | 0.77 | 0.72 | 0.66 | 0.69 | 0.58 | 0.60 | 0.69 |
| Depreciation | 1.31 | 1.36 | 1.42 | 1.39 | 1.41 | 1.43 | 1.49 | 1.50 | 1.61 | 1.68 | 1.70 | 1.68 | 1.69 |
| Profit before tax | 0.17 | 0.04 | 3.38 | 0.22 | 0.01 | 0.14 | 1.29 | 0.62 | 0.10 | 0.18 | 1.26 | 0.62 | 0.56 |
| Tax % | 64.71% | 425.00% | 11.54% | -59.09% | 0.00% | 57.14% | 46.51% | 30.65% | 20.00% | 44.44% | 26.98% | 38.71% | 57.14% |
| Net Profit | 0.06 | -0.13 | 2.99 | 0.36 | 0.01 | 0.06 | 0.68 | 0.42 | 0.08 | 0.11 | 0.92 | 0.39 | 0.24 |
| EPS in Rs | 0.09 | -0.19 | 4.29 | 0.52 | 0.01 | 0.09 | 0.98 | 0.60 | 0.11 | 0.16 | 1.32 | 0.56 | 0.34 |
Last Updated: December 27, 2025, 2:03 pm
Below is a detailed analysis of the quarterly data for Choksi Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 11.12 Cr.. The value appears to be declining and may need further review. It has decreased from 11.24 Cr. (Jun 2025) to 11.12 Cr., marking a decrease of 0.12 Cr..
- For Expenses, as of Sep 2025, the value is 8.19 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 8.34 Cr. (Jun 2025) to 8.19 Cr., marking a decrease of 0.15 Cr..
- For Operating Profit, as of Sep 2025, the value is 2.93 Cr.. The value appears strong and on an upward trend. It has increased from 2.90 Cr. (Jun 2025) to 2.93 Cr., marking an increase of 0.03 Cr..
- For OPM %, as of Sep 2025, the value is 26.35%. The value appears strong and on an upward trend. It has increased from 25.80% (Jun 2025) to 26.35%, marking an increase of 0.55%.
- For Other Income, as of Sep 2025, the value is 0.01 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Jun 2025) to 0.01 Cr., marking an increase of 0.01 Cr..
- For Interest, as of Sep 2025, the value is 0.69 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.60 Cr. (Jun 2025) to 0.69 Cr., marking an increase of 0.09 Cr..
- For Depreciation, as of Sep 2025, the value is 1.69 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.68 Cr. (Jun 2025) to 1.69 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.56 Cr.. The value appears to be declining and may need further review. It has decreased from 0.62 Cr. (Jun 2025) to 0.56 Cr., marking a decrease of 0.06 Cr..
- For Tax %, as of Sep 2025, the value is 57.14%. The value appears to be increasing, which may not be favorable. It has increased from 38.71% (Jun 2025) to 57.14%, marking an increase of 18.43%.
- For Net Profit, as of Sep 2025, the value is 0.24 Cr.. The value appears to be declining and may need further review. It has decreased from 0.39 Cr. (Jun 2025) to 0.24 Cr., marking a decrease of 0.15 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.34. The value appears to be declining and may need further review. It has decreased from 0.56 (Jun 2025) to 0.34, marking a decrease of 0.22.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:58 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22.16 | 24.45 | 25.10 | 28.63 | 30.40 | 33.74 | 28.16 | 25.69 | 30.04 | 34.44 | 36.70 | 41.78 | 44.14 |
| Expenses | 17.85 | 19.30 | 19.95 | 23.85 | 24.06 | 26.48 | 24.62 | 21.57 | 21.14 | 24.17 | 26.42 | 30.48 | 32.27 |
| Operating Profit | 4.31 | 5.15 | 5.15 | 4.78 | 6.34 | 7.26 | 3.54 | 4.12 | 8.90 | 10.27 | 10.28 | 11.30 | 11.87 |
| OPM % | 19.45% | 21.06% | 20.52% | 16.70% | 20.86% | 21.52% | 12.57% | 16.04% | 29.63% | 29.82% | 28.01% | 27.05% | 26.89% |
| Other Income | 0.10 | 0.63 | -0.05 | 0.86 | 0.35 | 0.25 | -2.80 | 0.49 | 0.12 | 2.47 | 0.16 | 0.07 | 0.06 |
| Interest | 1.19 | 1.57 | 1.23 | 1.47 | 1.59 | 1.54 | 1.89 | 2.82 | 3.23 | 3.52 | 3.06 | 2.72 | 2.56 |
| Depreciation | 1.59 | 2.83 | 2.73 | 2.86 | 3.16 | 3.68 | 4.56 | 4.60 | 5.43 | 5.50 | 5.71 | 6.50 | 6.75 |
| Profit before tax | 1.63 | 1.38 | 1.14 | 1.31 | 1.94 | 2.29 | -5.71 | -2.81 | 0.36 | 3.72 | 1.67 | 2.15 | 2.62 |
| Tax % | 28.83% | 36.23% | 36.84% | 32.06% | 29.90% | 30.13% | -32.05% | -7.12% | 44.44% | 13.71% | 32.93% | 29.30% | |
| Net Profit | 1.17 | 0.88 | 0.72 | 0.89 | 1.35 | 1.60 | -3.88 | -2.61 | 0.21 | 3.21 | 1.11 | 1.52 | 1.66 |
| EPS in Rs | 1.68 | 1.26 | 1.03 | 1.28 | 1.94 | 2.30 | -5.57 | -3.75 | 0.30 | 4.61 | 1.59 | 2.18 | 2.38 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -24.79% | -18.18% | 23.61% | 51.69% | 18.52% | -342.50% | 32.73% | 108.05% | 1428.57% | -65.42% | 36.94% |
| Change in YoY Net Profit Growth (%) | 0.00% | 6.60% | 41.79% | 28.07% | -33.17% | -361.02% | 375.23% | 75.31% | 1320.53% | -1493.99% | 102.36% |
Choksi Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 8% |
| 3 Years: | 12% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 32% |
| 3 Years: | 93% |
| TTM: | 28% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 33% |
| 5 Years: | 83% |
| 3 Years: | 86% |
| 1 Year: | 175% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 2% |
| 3 Years: | 7% |
| Last Year: | 7% |
Last Updated: September 5, 2025, 2:56 pm
Balance Sheet
Last Updated: December 4, 2025, 2:37 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 |
| Reserves | 13.35 | 12.35 | 13.07 | 14.16 | 15.43 | 17.04 | 13.26 | 10.78 | 10.94 | 14.14 | 15.25 | 16.64 | 17.53 |
| Borrowings | 11.45 | 11.65 | 13.68 | 11.20 | 12.43 | 17.05 | 31.64 | 39.15 | 37.29 | 32.41 | 30.87 | 29.15 | 28.87 |
| Other Liabilities | 6.93 | 6.70 | 8.81 | 8.32 | 9.85 | 14.28 | 13.14 | 9.48 | 9.22 | 6.84 | 8.86 | 12.57 | 11.87 |
| Total Liabilities | 38.70 | 37.67 | 42.53 | 40.65 | 44.68 | 55.34 | 65.01 | 66.38 | 64.42 | 60.36 | 61.95 | 65.33 | 65.24 |
| Fixed Assets | 23.98 | 19.28 | 17.64 | 22.23 | 28.62 | 34.81 | 33.08 | 50.32 | 46.56 | 44.83 | 43.43 | 47.61 | 45.83 |
| CWIP | 2.23 | 2.73 | 8.99 | 4.28 | 0.00 | 3.23 | 13.06 | 0.50 | 1.67 | 0.31 | 2.99 | 0.00 | 0.48 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 12.49 | 15.66 | 15.90 | 14.14 | 16.06 | 17.30 | 18.87 | 15.56 | 16.19 | 15.22 | 15.53 | 17.72 | 18.93 |
| Total Assets | 38.70 | 37.67 | 42.53 | 40.65 | 44.68 | 55.34 | 65.01 | 66.38 | 64.42 | 60.36 | 61.95 | 65.33 | 65.24 |
Below is a detailed analysis of the balance sheet data for Choksi Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 6.97 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.97 Cr..
- For Reserves, as of Sep 2025, the value is 17.53 Cr.. The value appears strong and on an upward trend. It has increased from 16.64 Cr. (Mar 2025) to 17.53 Cr., marking an increase of 0.89 Cr..
- For Borrowings, as of Sep 2025, the value is 28.87 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 29.15 Cr. (Mar 2025) to 28.87 Cr., marking a decrease of 0.28 Cr..
- For Other Liabilities, as of Sep 2025, the value is 11.87 Cr.. The value appears to be improving (decreasing). It has decreased from 12.57 Cr. (Mar 2025) to 11.87 Cr., marking a decrease of 0.70 Cr..
- For Total Liabilities, as of Sep 2025, the value is 65.24 Cr.. The value appears to be improving (decreasing). It has decreased from 65.33 Cr. (Mar 2025) to 65.24 Cr., marking a decrease of 0.09 Cr..
- For Fixed Assets, as of Sep 2025, the value is 45.83 Cr.. The value appears to be declining and may need further review. It has decreased from 47.61 Cr. (Mar 2025) to 45.83 Cr., marking a decrease of 1.78 Cr..
- For CWIP, as of Sep 2025, the value is 0.48 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 0.48 Cr., marking an increase of 0.48 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 18.93 Cr.. The value appears strong and on an upward trend. It has increased from 17.72 Cr. (Mar 2025) to 18.93 Cr., marking an increase of 1.21 Cr..
- For Total Assets, as of Sep 2025, the value is 65.24 Cr.. The value appears to be declining and may need further review. It has decreased from 65.33 Cr. (Mar 2025) to 65.24 Cr., marking a decrease of 0.09 Cr..
However, the Borrowings (28.87 Cr.) are higher than the Reserves (17.53 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -7.14 | -6.50 | -8.53 | -6.42 | -6.09 | -9.79 | -28.10 | -35.03 | -28.39 | -22.14 | -20.59 | -17.85 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 117.27 | 126.15 | 124.77 | 112.19 | 118.62 | 95.09 | 90.60 | 115.94 | 125.03 | 112.87 | 103.33 | 98.46 |
| Inventory Days | 0.00 | 0.00 | 0.00 | 28.27 | 30.50 | 37.89 | 20.28 | 15.62 | 46.09 | 34.68 | 51.33 | 65.94 |
| Days Payable | 591.13 | 594.31 | 660.70 | 723.24 | 685.97 | 741.06 | 297.29 | 560.33 | 639.34 | |||
| Cash Conversion Cycle | 117.27 | 126.15 | 124.77 | -450.67 | -445.18 | -527.72 | -612.36 | -554.41 | -569.95 | -149.73 | -405.67 | -474.95 |
| Working Capital Days | 8.73 | 29.26 | 3.34 | -23.71 | -18.37 | 28.02 | 21.13 | -49.73 | -23.33 | 11.66 | -49.13 | -71.29 |
| ROCE % | 9.25% | 7.94% | 7.51% | 7.33% | 10.51% | 10.09% | -1.48% | 0.00% | 6.40% | 9.16% | 8.87% | 9.20% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 2.19 | 1.59 | 4.61 | 0.30 | -3.74 |
| Diluted EPS (Rs.) | 2.19 | 1.59 | 4.61 | 0.30 | -3.74 |
| Cash EPS (Rs.) | 11.52 | 9.80 | 12.50 | 8.09 | 2.86 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 33.89 | 31.89 | 30.31 | 25.70 | 25.48 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 33.89 | 31.89 | 30.31 | 25.70 | 25.48 |
| Revenue From Operations / Share (Rs.) | 59.99 | 52.68 | 49.45 | 43.13 | 36.88 |
| PBDIT / Share (Rs.) | 16.23 | 14.90 | 15.01 | 12.93 | 6.62 |
| PBIT / Share (Rs.) | 6.89 | 6.70 | 7.12 | 5.13 | 0.01 |
| PBT / Share (Rs.) | 3.09 | 2.39 | 5.34 | 0.52 | -4.03 |
| Net Profit / Share (Rs.) | 2.19 | 1.59 | 4.61 | 0.29 | -3.74 |
| PBDIT Margin (%) | 27.04 | 28.29 | 30.35 | 29.97 | 17.95 |
| PBIT Margin (%) | 11.49 | 12.72 | 14.39 | 11.90 | 0.03 |
| PBT Margin (%) | 5.15 | 4.53 | 10.80 | 1.22 | -10.93 |
| Net Profit Margin (%) | 3.64 | 3.02 | 9.32 | 0.68 | -10.15 |
| Return on Networth / Equity (%) | 6.45 | 4.99 | 15.20 | 1.15 | -14.69 |
| Return on Capital Employeed (%) | 11.58 | 10.83 | 10.36 | 7.31 | 0.02 |
| Return On Assets (%) | 2.33 | 1.79 | 5.31 | 0.32 | -3.92 |
| Long Term Debt / Equity (X) | 0.64 | 0.81 | 1.12 | 1.54 | 1.77 |
| Total Debt / Equity (X) | 1.19 | 1.32 | 1.44 | 1.94 | 1.91 |
| Asset Turnover Ratio (%) | 0.65 | 0.59 | 0.55 | 0.45 | 0.39 |
| Current Ratio (X) | 0.68 | 0.77 | 1.11 | 0.90 | 0.80 |
| Quick Ratio (X) | 0.66 | 0.75 | 1.10 | 0.88 | 0.79 |
| Inventory Turnover Ratio (X) | 90.75 | 8.94 | 9.63 | 10.95 | 17.75 |
| Interest Coverage Ratio (X) | 4.27 | 3.45 | 2.99 | 2.81 | 1.64 |
| Interest Coverage Ratio (Post Tax) (X) | 1.57 | 1.37 | 1.27 | 1.06 | 0.07 |
| Enterprise Value (Cr.) | 111.15 | 58.14 | 53.31 | 52.04 | 39.01 |
| EV / Net Operating Revenue (X) | 2.66 | 1.58 | 1.55 | 1.73 | 1.52 |
| EV / EBITDA (X) | 9.84 | 5.60 | 5.10 | 5.78 | 8.46 |
| MarketCap / Net Operating Revenue (X) | 2.00 | 0.80 | 0.67 | 0.58 | 0.21 |
| Price / BV (X) | 3.55 | 1.33 | 1.10 | 0.98 | 0.30 |
| Price / Net Operating Revenue (X) | 2.00 | 0.80 | 0.67 | 0.58 | 0.21 |
| EarningsYield | 0.01 | 0.03 | 0.13 | 0.01 | -0.47 |
After reviewing the key financial ratios for Choksi Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 2.19. This value is below the healthy minimum of 5. It has increased from 1.59 (Mar 24) to 2.19, marking an increase of 0.60.
- For Diluted EPS (Rs.), as of Mar 25, the value is 2.19. This value is below the healthy minimum of 5. It has increased from 1.59 (Mar 24) to 2.19, marking an increase of 0.60.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.52. This value is within the healthy range. It has increased from 9.80 (Mar 24) to 11.52, marking an increase of 1.72.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 33.89. It has increased from 31.89 (Mar 24) to 33.89, marking an increase of 2.00.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 33.89. It has increased from 31.89 (Mar 24) to 33.89, marking an increase of 2.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 59.99. It has increased from 52.68 (Mar 24) to 59.99, marking an increase of 7.31.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 16.23. This value is within the healthy range. It has increased from 14.90 (Mar 24) to 16.23, marking an increase of 1.33.
- For PBIT / Share (Rs.), as of Mar 25, the value is 6.89. This value is within the healthy range. It has increased from 6.70 (Mar 24) to 6.89, marking an increase of 0.19.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.09. This value is within the healthy range. It has increased from 2.39 (Mar 24) to 3.09, marking an increase of 0.70.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.19. This value is within the healthy range. It has increased from 1.59 (Mar 24) to 2.19, marking an increase of 0.60.
- For PBDIT Margin (%), as of Mar 25, the value is 27.04. This value is within the healthy range. It has decreased from 28.29 (Mar 24) to 27.04, marking a decrease of 1.25.
- For PBIT Margin (%), as of Mar 25, the value is 11.49. This value is within the healthy range. It has decreased from 12.72 (Mar 24) to 11.49, marking a decrease of 1.23.
- For PBT Margin (%), as of Mar 25, the value is 5.15. This value is below the healthy minimum of 10. It has increased from 4.53 (Mar 24) to 5.15, marking an increase of 0.62.
- For Net Profit Margin (%), as of Mar 25, the value is 3.64. This value is below the healthy minimum of 5. It has increased from 3.02 (Mar 24) to 3.64, marking an increase of 0.62.
- For Return on Networth / Equity (%), as of Mar 25, the value is 6.45. This value is below the healthy minimum of 15. It has increased from 4.99 (Mar 24) to 6.45, marking an increase of 1.46.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.58. This value is within the healthy range. It has increased from 10.83 (Mar 24) to 11.58, marking an increase of 0.75.
- For Return On Assets (%), as of Mar 25, the value is 2.33. This value is below the healthy minimum of 5. It has increased from 1.79 (Mar 24) to 2.33, marking an increase of 0.54.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.64. This value is within the healthy range. It has decreased from 0.81 (Mar 24) to 0.64, marking a decrease of 0.17.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.19. This value exceeds the healthy maximum of 1. It has decreased from 1.32 (Mar 24) to 1.19, marking a decrease of 0.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.65. It has increased from 0.59 (Mar 24) to 0.65, marking an increase of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1.5. It has decreased from 0.77 (Mar 24) to 0.68, marking a decrease of 0.09.
- For Quick Ratio (X), as of Mar 25, the value is 0.66. This value is below the healthy minimum of 1. It has decreased from 0.75 (Mar 24) to 0.66, marking a decrease of 0.09.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 90.75. This value exceeds the healthy maximum of 8. It has increased from 8.94 (Mar 24) to 90.75, marking an increase of 81.81.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.27. This value is within the healthy range. It has increased from 3.45 (Mar 24) to 4.27, marking an increase of 0.82.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.57. This value is below the healthy minimum of 3. It has increased from 1.37 (Mar 24) to 1.57, marking an increase of 0.20.
- For Enterprise Value (Cr.), as of Mar 25, the value is 111.15. It has increased from 58.14 (Mar 24) to 111.15, marking an increase of 53.01.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.66. This value is within the healthy range. It has increased from 1.58 (Mar 24) to 2.66, marking an increase of 1.08.
- For EV / EBITDA (X), as of Mar 25, the value is 9.84. This value is within the healthy range. It has increased from 5.60 (Mar 24) to 9.84, marking an increase of 4.24.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has increased from 0.80 (Mar 24) to 2.00, marking an increase of 1.20.
- For Price / BV (X), as of Mar 25, the value is 3.55. This value exceeds the healthy maximum of 3. It has increased from 1.33 (Mar 24) to 3.55, marking an increase of 2.22.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has increased from 0.80 (Mar 24) to 2.00, marking an increase of 1.20.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Choksi Laboratories Ltd:
- Net Profit Margin: 3.64%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.58% (Industry Average ROCE: 17.2%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 6.45% (Industry Average ROE: 13.02%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.57
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.66
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 53.2 (Industry average Stock P/E: 44.6)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.19
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 3.64%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Research Services | Survey No 9/1, Near Tulsiyana Industrial Park, Indore Madhya Pradesh 453555 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sunil Choksi | Managing Director |
| Mrs. Stela Choksi | Whole Time Director |
| Ms. Himika Choksi | Whole Time Director |
| Mr. Vyangesh Choksi | Whole Time Director |
| Mr. Raghmendra Singh | Independent Director |
| Mrs. Meenaxi Patidar | Independent Director |
| Mrs. Prachi Mantri | Independent Director |
| Mrs. Abha Shastri | Independent Director |
FAQ
What is the intrinsic value of Choksi Laboratories Ltd?
Choksi Laboratories Ltd's intrinsic value (as of 08 January 2026) is ₹101.31 which is 20.23% lower the current market price of ₹127.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹88.3 Cr. market cap, FY2025-2026 high/low of ₹237/97.6, reserves of ₹17.53 Cr, and liabilities of ₹65.24 Cr.
What is the Market Cap of Choksi Laboratories Ltd?
The Market Cap of Choksi Laboratories Ltd is 88.3 Cr..
What is the current Stock Price of Choksi Laboratories Ltd as on 08 January 2026?
The current stock price of Choksi Laboratories Ltd as on 08 January 2026 is ₹127.
What is the High / Low of Choksi Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Choksi Laboratories Ltd stocks is ₹237/97.6.
What is the Stock P/E of Choksi Laboratories Ltd?
The Stock P/E of Choksi Laboratories Ltd is 53.2.
What is the Book Value of Choksi Laboratories Ltd?
The Book Value of Choksi Laboratories Ltd is 35.2.
What is the Dividend Yield of Choksi Laboratories Ltd?
The Dividend Yield of Choksi Laboratories Ltd is 0.00 %.
What is the ROCE of Choksi Laboratories Ltd?
The ROCE of Choksi Laboratories Ltd is 9.20 %.
What is the ROE of Choksi Laboratories Ltd?
The ROE of Choksi Laboratories Ltd is 6.63 %.
What is the Face Value of Choksi Laboratories Ltd?
The Face Value of Choksi Laboratories Ltd is 10.0.